Superworth

Lunai Bioworks LNAI

Drug Manufacturers - General, Healthcare
$0.29
−37.32%
Market cap
$1.5M
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
n/m
one or more of the four quarters through 2026-06-30 missing
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
n/m
one or more of the four quarters through 2026-06-30 missing
Net margin
n/m
one or more of the four quarters through 2026-06-30 missing
Free cash flow yield
n/m
not a meaningful number

Lunai Bioworks' trailing earnings are negative, so it has no PE.

Charts

Financials

Income statement for LNAI, by quarter
Income statementQ1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26
n/an/an/an/an/an/an/an/an/an/a$20.9Kn/a
Cost of revenuen/an/an/an/an/an/an/an/an/an/an/an/a
Gross profitn/an/an/an/an/an/an/an/an/an/a$20.9Kn/a
R&D$566.6K−78%$620.5K+90%$1.1M+355%$434.5K−56%$390.2K−31%$161.1K−74%−$94.1K$80.2K−82%$24.4K−94%$45.9K−72%$15.9Kn/a
SG&A$8.3M+82%$3.6M−10%$7.7M+102%$5M+69%$5.3M−36%$4.4M+20%$4.2M−45%$4M−20%$2.4M−55%$1.8M−59%$1.4M−66%n/a
−$8.9M+24%−$4.3M−2%−$51.4M+1165%−$17.1M−25%−$53.3M+500%−$4.5M+7%−$4.2M−92%−$126.9M+642%−$3.3M−94%−$1.8M−60%−$1.5M−65%n/a
Interest expense$179.3K+88%$275K+196%$303.8K+148%$253.3K−6%$250.1K+40%$98.9K−64%$188.7K−38%$188K−26%$122.4K−51%$121.5K+23%$108.1K−43%n/a
Pre-tax income−$9.2M+19%n/an/an/an/an/an/an/an/an/an/an/a
n/an/an/an/an/an/an/an/an/an/an/an/a
Net income−$9.2M+19%−$4.5M+2%−$59M+1263%−$15.7M−32%−$44.2M+382%−$7.3M+60%$189.2K−$126.7M+706%$2.8M−$1.8M−75%−$2.6M−$2M−98%
−$11.20+0%−$5.60−13%−$43.20+575%−$8.00−75%−$22.08+97%−$3.60−36%$0.00−$57.60+620%$1.04−$0.64−82%−$0.80n/a
806K+17%823.2K+19%1.4M+95%1.9M+158%2M+148%2M+146%2M+50%2.2M+17%2.8M+41%2.9M+45%3.1M+53%n/a

SG&A: Q1 FY12: 6 months less the 3 months printed beside them.

Operating income: Q1 FY12: 6 months less the 3 months printed beside them.

Pre-tax income: Q1 FY12: 6 months less the 3 months printed beside them.

Net income: Q1 FY12: 6 months less the 3 months printed beside them.

EPS, diluted: 24 periods, Q2 FY12 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 10 periods, Q4 FY12 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY15: a loss quarter: its basic count, share-days: the 6-month average less the 3-month, weighted by days. Q4 FY19: share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Healthcare nearest Lunai Bioworks' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
LNAILunai Bioworks$1.5Mn/mn/an/mn/mn/m
OXBROXBRIDGE RE HOLDINGS$7.7M47.5×9.6×2.8×+40%4.7%
EDUCEducational Development$8.7M5.4×11.3×0.4×−32%8.6%
GTIMGood Times Restaurants$13.6M6.1×13.6×0.1×−6%1.7%
Peer median$8.7M6.1×11.3×0.4×−6%4.7%

More on Lunai Bioworks

Each number over time

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .